Smart bomb combination curbs metastatic triple-negative breast cancer in models

A two-part treatment that delivered a targeted “smart bomb” drug to triple-negative breast cancer cells while disrupting their mitochondria killed cancer cells, slowed tumor growth and limited cancer spread more effectively than either treatment alone in two preclinical models of metastatic disease. The experimental study, published Aug. 18, 2026, in Cell Reports Medicine, provides a rationale for further laboratory investigation but does not establish that the combination is safe or effective in people.

Researchers at The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute developed the approach. Its first component is an antibody-drug conjugate, or ADC, targeting CD276, a protein on the surface of some cancer cells. The second component is cmLumiOpto, a gene therapy that disrupts mitochondria, the structures that produce energy for cells. The ADC links an antibody to an anticancer drug: the antibody recognizes CD276 on a cancer cell and carries the drug to it, potentially limiting damage to healthy cells. CmLumiOpto attacks through a separate mechanism by targeting mitochondria and interfering with the energy supply that cancer cells need to survive.

Triple-negative breast cancer, commonly abbreviated TNBC, does not have estrogen or progesterone receptors and does not have high levels of the HER2 protein. Many breast cancer drugs work by targeting one of these features, so fewer targeted treatments are available for TNBC. The cancer is also more likely to spread and return after treatment, which can lead to poorer long-term survival. The new study examined whether a CD276-targeted ADC could work against TNBC that had spread and whether adding mitochondrial disruption would improve the results. The authors’ central hypothesis was that cancer cells might be more vulnerable when simultaneously attacked through a cell-surface target and their energy supply.

Across both metastatic TNBC models, the combination produced greater reductions in cancer-cell viability, slower tumor growth and less spread than either the CD276-targeted ADC or cmLumiOpto used alone. These findings extend earlier preclinical work in which the team developed antibodies targeting CD276 and used them to construct antibody-drug conjugates. Those earlier treatments reduced the amount of cancer in preclinical models of TNBC and non-small cell lung cancer. The current experiment provides evidence that adding a mitochondrial-disrupting treatment may improve the activity of a CD276-targeted ADC in metastatic TNBC models, although the reported results remain limited to experimental systems.

Corresponding author Xiaoguang “Margaret” Liu, a professor in Ohio State University’s College of Engineering and a member of the cancer center’s Translational Therapeutics Program, described the results as an early step. She said the approach could become a more effective treatment with fewer side effects than current options only if it continues to work in laboratory studies and clinical trials. Senior co-author Lufang Zhou, a professor of surgery and biomedical engineering, said the lower-dose findings warrant further study because reducing treatment exposure could help limit dose-related side effects, but that possibility requires experimental evaluation. The researchers also identified unresolved questions about optimal doses and schedules, long-term safety, possible adverse effects and whether tumors might stop responding. More laboratory research is required before the combination can advance to clinical trials, with additional funding and a commercial partner identified as next steps. Separately, development of the licensed CD276-targeted ADC is moving forward through studies and manufacturing preparation intended to support a future clinical trial application.

Subject of Research: Preclinical evaluation of a CD276-targeted antibody-drug conjugate combined with cmLumiOpto for metastatic triple-negative breast cancer.

Article Title: ‘Smart bomb’ combination attacks triple-negative breast cancer in preclinical study

Article References: ‘Smart bomb’ combination attacks triple-negative breast cancer in preclinical study. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: triple-negative breast cancer, antibody-drug conjugate, CD276, cmLumiOpto, mitochondrial disruption, gene therapy, preclinical models, metastatic cancer, tumor growth, cancer-cell targeting, Smart, bomb